文献速递中医内科中药与中成药合理使用

麝香保心丸在稳定型冠心病不同体重亚组中的疗效与安全性

Efficacy and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease across different weight subgroups.
PubMed 文献 · J Ethnopharmacol · 2025-01-08

该研究为多中心随机双盲安慰剂对照Ⅳ期试验的亚组分析,共纳入2646例稳定型冠心病患者,按体重65kg分为两组。结果显示体重<65kg者联用麝香保心丸可显著降低主要不良心血管事件风险(HR=0.241),而≥65kg者未见显著差异,两组不良事件相似。

要点

  • 体重<65kg的稳定型冠心病患者联用麝香保心丸可降低MACEs风险。
  • 体重≥65kg患者联用麝香保心丸未观察到显著获益,需优化剂量策略。
  • 两个体重亚组中麝香保心丸的不良事件发生率与安慰剂相似。

核心结论

  • 在体重<65kg的稳定型冠心病患者中,麝香保心丸联合OMT可降低MACEs风险且安全性可接受。
  • 在体重≥65kg的患者中,麝香保心丸联合OMT未见显著疗效差异,需进一步研究优化剂量。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照Ⅳ期临床试验的亚组分析。
  • 共纳入2646例接受OMT的稳定型冠心病患者,按体重65kg为界分为<65kg组(916例)和≥65kg组(1730例)。
  • 患者随机接受麝香保心丸或安慰剂治疗24个月。

主要发现

  • 体重<65kg组中,麝香保心丸组主要疗效终点发生率为0.65%,安慰剂组为2.64%(P=0.018)。
  • 体重<65kg组中,麝香保心丸组MACEs风险显著降低(HR=0.241,95%CI:0.068-0.856;P=0.0168)。
  • 体重≥65kg组中,主要和次要疗效终点的发生率及风险在两组间均无显著差异(所有P>0.05)。
  • 两个体重亚组中,麝香保心丸组与安慰剂组的不良事件相似。

关键数值与推荐

  • 主要疗效终点为MACEs复合终点,包括心血管死亡、非致死性心肌梗死和非致死性卒中。
  • 次要疗效终点为全因死亡、非致死性心肌梗死、非致死性卒中、不稳定型心绞痛或心力衰竭住院以及冠状动脉血运重建的复合终点。
  • 体重<65kg组中,麝香保心丸组主要终点发生率0.65% vs 安慰剂组2.64%(P=0.018),HR=0.241(95%CI:0.068-0.856;P=0.0168)。

临床怎么用

  • 对于体重<65kg的稳定型冠心病患者,可考虑在OMT基础上联用麝香保心丸以降低MACEs风险。
  • 对于体重≥65kg的患者,目前证据未显示联用麝香保心丸的显著获益,需个体化评估并进一步研究剂量策略。

局限性

  • 本研究为亚组分析,结果需在专门设计的随机对照试验中进一步验证。
  • 体重≥65kg患者的剂量优化策略尚不明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Shexiang Baoxin Pill (MUSKARDIA), a traditional Chinese patent medicine, plays a crucial role in both preventing and treating diverse cardiovascular diseases, including coronary heart disease, myocardial infarction (MI), and heart failure. Preclinical research has demonstrated that the cardioprotective effects of MUSKARDIA are achieved through multiple pathways, such as enhancing coronary artery dilation, fostering new blood vessel growth, reducing inflammation and oxidative stress, improving lipid metabolism, and protecting vascular endothelium. AIM OF THE STUDY: This subgroup analysis aimed to evaluate the efficacy and safety of Shexiang Baoxin Pill (MUSKARDIA) plus optimal medical therapy (OMT) across different weight categories in treating stable coronary artery disease (CAD). METHODS: This investigation was a subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled phase IV clinical study. Patients receiving OMT were randomly assigned to either MUSKARDIA or placebo group for a 24-month period. This analysis focused on body weight as a distinguishing factor, using 65 kg as the cutoff. The primary efficacy endpoint was the composite of major adverse cardiovascular events (MACEs), including cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke. Secondary efficacy endpoint comprised a composite of all-cause mortality, non-fatal MI, non-fatal stroke, hospitalizations for unstable angina or heart failure, and coronary revascularization procedures. RESULTS: A total of 2646 patients were included in the analysis, with 916 patients weighing less than 65 kg and 1730 patients weighing 65 kg or more. The median ages were 68 (range: 35-90) years and 62 (range: 29-90) in these two subgroups, respectively. For patients weighing less than 65 kg, the MUSKARDIA group exhibited a significantly lower incidence of the primary efficacy endpoint (0.65%) compared to the placebo group (2.64%) (P = 0.018), with a reduced risk of MACEs (HR = 0.241, 95%CI: 0.068-0.856; P = 0.0168). Conversely, in patients weighing 65 kg or more, no significant differences were observed in the incidence rates or risks of primary or secondary efficacy endpoints between the MUSKARDIA and placebo groups (All P > 0.05). Adverse events were similar between two groups across both weight subgroups. CONCLUSIONS: MUSKARDIA plus OMT demonstrated promising efficacy and acceptable safety in CAD patients weighing less than 65 kg, potentially reducing the risk of MACEs. For patients weighing 65 kg or more, further investigation is needed to optimize dosing strategies.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhou J, Shi H, Zhao Y, et al. Efficacy and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease across different weight subgroups. J Ethnopharmacol. 2025. PMID: 39793776. doi:10.1016/j.jep.2025.119341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。